Allarity Therapeutics, Inc. 8K

Allarity Therapeutics announced the S-1 filing and planned Nasdaq IPO of its sponsored SPAC, Allarity Acquisition Corp., with an anticipated $100–$115 million raise and expected 25% post-offering sponsor ownership, without altering Allarity’s existing liquidity outlook.

On September 11, 2026, Allarity Therapeutics, Inc. announced that Allarity Acquisition Corp., a newly formed special purpose acquisition company sponsored by ALLR Sponsor LLC (a wholly owned subsidiary of Allarity), publicly filed a Registration Statement on Form S-1 with the SEC for a proposed initial public offering of its units on Nasdaq under the symbol ALLNU, with an expected base offering size of $100 million (up to $115 million with the underwriters’ over-allotment option); the sponsor is expected to own approximately 25% of the SPAC’s ordinary shares post-offering, Jesper Hoiland will serve as chairman of the SPAC’s board, and Allarity stated that this offering does not change its prior expectation that it has sufficient working capital to fund operations into the summer of 2028.

Filing Facts

CIK

1860657

Ticker

-

Form

8K

Source Type

sec

Accession

0001213900-26-099576

Alert Tier

7